Catalent (CTLT) Downgraded by BidaskClub to Hold

Catalent (NYSE:CTLT) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, November 14th.

A number of other equities research analysts have also commented on the company. Zacks Investment Research lowered Catalent from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Bank of America restated a “buy” rating and issued a $40.00 price objective (up previously from $38.00) on shares of Catalent in a research report on Tuesday, August 29th. William Blair restated an “ourperform” rating on shares of Catalent in a research report on Tuesday, August 29th. ValuEngine upgraded Catalent from a “hold” rating to a “buy” rating in a research report on Thursday, September 7th. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $45.00 price objective on shares of Catalent in a research report on Tuesday, August 29th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $44.25.

Shares of Catalent (NYSE CTLT) traded down $0.99 during trading on Tuesday, reaching $38.80. 612,803 shares of the company’s stock were exchanged, compared to its average volume of 894,161. Catalent has a fifty-two week low of $23.03 and a fifty-two week high of $43.39. The company has a debt-to-equity ratio of 2.01, a current ratio of 2.91 and a quick ratio of 2.49. The company has a market capitalization of $5,154.93, a P/E ratio of 27.13, a PEG ratio of 2.49 and a beta of 1.42.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Monday, November 6th. The company reported $0.21 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.01. The firm had revenue of $543.90 million for the quarter, compared to the consensus estimate of $490.75 million. Catalent had a net margin of 5.01% and a return on equity of 23.97%. The company’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.16 earnings per share. equities research analysts predict that Catalent will post 1.46 EPS for the current year.

In other news, Director Uwe Roehrhoff acquired 7,500 shares of Catalent stock in a transaction that occurred on Tuesday, November 21st. The stock was purchased at an average cost of $39.22 per share, with a total value of $294,150.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.70% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of CTLT. Janus Henderson Group PLC acquired a new stake in shares of Catalent during the 2nd quarter worth about $239,629,000. BlackRock Inc. increased its position in shares of Catalent by 15.2% during the 2nd quarter. BlackRock Inc. now owns 17,512,661 shares of the company’s stock worth $614,695,000 after purchasing an additional 2,316,849 shares during the last quarter. Eagle Asset Management Inc. increased its position in shares of Catalent by 290.9% during the 3rd quarter. Eagle Asset Management Inc. now owns 1,153,710 shares of the company’s stock worth $47,636,000 after purchasing an additional 858,600 shares during the last quarter. AJO LP acquired a new stake in shares of Catalent during the 2nd quarter worth about $26,130,000. Finally, Macquarie Group Ltd. increased its position in shares of Catalent by 60.2% during the 2nd quarter. Macquarie Group Ltd. now owns 1,786,764 shares of the company’s stock worth $62,715,000 after purchasing an additional 671,429 shares during the last quarter. 99.44% of the stock is owned by institutional investors and hedge funds.

WARNING: “Catalent (CTLT) Downgraded by BidaskClub to Hold” was first reported by BBNS and is the property of of BBNS. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://baseballnewssource.com/markets/catalent-inc-ctlt-downgraded-by-bidaskclub/1782534.html.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.